Trade Mark Journal No.2024/030 26 July 2024

UK00004076043 16 July 2024 (5)

SIGMIVY

International priority date claimed: 16 January 2024 (United States of America) (98359118)

Class 5: Pharmaceutical preparations; pharmaceutical preparations based upon human allogeneic bone marrow mesenchymal stem cell derived extracellular vesicles (EVs) containing secretomes for the treatment of immunomodulatory, inflammatory, or autoimmune conditions such as respiratory diseases, neurological diseases, tissue injury and repair, gastrointestinal diseases, joint diseases and transplant.

Direct Biologics LLC

Representative: Taylor Wessing LLP